Christopher Missling

Christopher Missling

Company: Anavex Life Sciences

Job title: President & CEO


Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for neurodegenerative and neurodevelopmental diseases, like Alzheimer’s disease, and Parkinson’s disease, as well as, Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management. 


Cross-Learnings from Mechanisms of Action Underlying Protein Conformational Disorders 2:50 pm

How to evaluate the safety and tolerability of novel protein misfolding  therapeutics as assessed through clinical development How can the commonalities in underlying molecular pathology be used to inform the development of new treatment options for protein-misfolding diseases?  How can you leverage a clinical developmental strategy to address a range of diseases caused by protein…Read more

day: Day One

Panel Discussion: Conducting a Strategic Analysis of Protein Misfolding Therapeutics 2:00 pm

• What are the strengths of companies active in developing protein misfolding therapeutics? • What is a bird’s eye view of the space in terms of how money has flowed in/out? • What do companies in this space need to change or improve to accelerate their scientific progress? • What is the market opportunity and…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.